Cambridge, MA, United States

Mersana Therapeutics

www.mersana.com
Cambridge, MA, United States

Time filter

Source Type

Patent
Mersana Therapeutics | Date: 2016-11-04

This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.


Patent
Mersana Therapeutics | Date: 2016-09-08

A terminally modified polymer is provided herein. At least one terminus of the polymer is O(CH_(2))_(2)-L^(M )or OCH_(2)CH(OH)CH_(2)CR^(1)CR^(2)R^(3). L^(M), R^(1), R^(2), and R^(3 )are defined herein Also disclosed are terminal conjugates comprising the polymer and a pharmaceutically useful modifier, as well as compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.


Patent
Mersana Therapeutics | Date: 2017-04-26

Provision of fully human monoclonal antibodies that recognize HER2, and methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.


Patent
Mersana Therapeutics | Date: 2015-06-18

A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders, such as cancer in a subject having low HER2 expression with the conjugates or their compositions are also described.


Patent
Mersana Therapeutics | Date: 2015-06-18

This invention provides fully human monoclonal antibodies that recognize HER2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications.


Patent
Mersana Therapeutics | Date: 2014-08-12

Auristatin compounds and conjugates thereof are provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L^(D)-D, the protein based recognition-molecule being connected to the polymeric carrier by L^(P). Each occurrence of D is independently an Auristatin compound. L^(D )and L^(P )are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.


Patent
Mersana Therapeutics | Date: 2014-08-12

A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L^(D)-D, the protein based recognition-molecule being connected to the polymeric carrier by L^(P). Each occurrence of D is independently a therapeutic agent having a molecular weight 5 kDa. L^(D )and L^(P )are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.


Patent
Mersana Therapeutics | Date: 2015-08-24

A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L^(D)-D, the protein based recognition-molecule being connected to the polymeric carrier by L^(P). Each occurrence of D is independently a therapeutic agent having a molecular weight 5 kDa. L^(D )and L^(P )are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.


Patent
Mersana Therapeutics | Date: 2016-01-19

Auristatin compounds and conjugates thereof are provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L^(D)-D, the protein based recognition-molecule being connected to the polymeric carrier by L^(P). Each occurrence of D is independently an Auristatin compound. L^(D )and L^(P )are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.


Patent
Mersana Therapeutics | Date: 2014-01-16

A drug conjugate is provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -L^(D)-D, the protein based recognition-molecule being connected to the polymeric carrier by L^(P). Each occurrence of D is independently a therapeutic agent having a molecular weight 5 kDa. L^(D )and L^(P )are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

Loading Mersana Therapeutics collaborators
Loading Mersana Therapeutics collaborators